Skip to content
Screener

4D Molecular Therapeutics FDMT Q4 2025 Annual earnings

Reported March 18, 2026 · Before market open

Revenue$85.1MBeat by $58.1M
EPS$0.43Beat by $0.96
Revenue estimate$27.0M
EPS estimate-$0.53

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$3.5M
EPS estimate-$1.04

Financials

Q4 2025

Income statement

See full
Revenue$85.1M+8,508,900%
Operating income-+100%

Balance sheet

See full
Cash & equivalents$60.2M-59.7%
Total debt$21.4M-13.0%
Total equity$505.7M-1.0%
Total assets$566.7M+1.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$428.51M+66.4%
Enterprise value$389.69M+194%
P/S5×-6,954×

Profitability

See full
Operating margin-204.5%-102pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio9.4×-5.5×

Segments

By product

See full
Collaboration And License Revenue$85.1M+8,508,900%

FAQ

When did 4D Molecular Therapeutics report Q4 2025 earnings?
4D Molecular Therapeutics (FDMT) reported Q4 2025 earnings on March 18, 2026 before market open.
What were 4D Molecular Therapeutics's Q4 2025 revenue and EPS?
4D Molecular Therapeutics reported revenue of $85.1M and eps of $0.43 for Q4 2025.
Did 4D Molecular Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $27.0M by $58.1M. EPS beat the consensus estimate of $-0.53 by $0.96.
How did 4D Molecular Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8509800.0% from $1.0K a year earlier.
Where can I find 4D Molecular Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-113949) and the 10-K periodic report (0001193125-26-114075) directly on SEC EDGAR. The filing index links above go to sec.gov.